UnknownPHASE1, PHASE2NCT03392909

Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Studying Dystrophic epidermolysis bullosa

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Southern California
Principal Investigator
David T. Woodley, MD
Professor, University of Southern California
Intervention
Gentamicin(drug)
Enrollment
9 enrolled
Eligibility
7 years · All sexes
Timeline
2018 – 2023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03392909 on ClinicalTrials.gov

Other trials for Dystrophic epidermolysis bullosa

Additional recruiting or active studies for the same condition.

See all trials for Dystrophic epidermolysis bullosa →

← Back to all trials